Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

A, Conconi; G, Martinelli; C, Thiéblemont; AJ, Ferreri; L, Devizzi; F, Peccatori; M, Ponzoni; E, Pedrinis; S, Dell'Oro; G, Pruneri; V, Filipazzi; PY, Dietrich; AM, Gianni; B, Coiffier; F, Cavalli; E, Zucca

doi:10.1182/blood-2002-11-3496

Public

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

Shared by NobleBlocks on Jul 3, 2003 • 12:00 AM UTC

Authors:

Conconi A

Martinelli G

Thiéblemont C

Abstract

The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The prim...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!